Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Faricimab versus aflibercept preconditioning before vitrectomy in proliferative diabetic retinopathy
ChiCTR2500100448Phase 4Not yet recruiting
- Sponsor
- Foshan Second People's Hospital
- Start
- Apr 2025
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of faricimab and aflibercept in diabetic retinopathy (DR) and proliferative diabetic retinopathy (PDR) (2 arms), sponsored by Foshan Second People's Hospital. Primary endpoints: Aqueous humor cytokines and Visual acuity. Planned start Apr 2025; status: not yet recruiting.
02
Drugs
faricimabaflibercept
03
Conditions
diabetic retinopathy (DR)proliferative diabetic retinopathy (PDR)
Beyond the preview
Go deeper on ChiCTR2500100448.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500100448.